Αποτελέσματα Αναζήτησης
There are three broad approaches to treating chronic migraine: lifestyle and trigger management, acute treatments (i.e. those taken during attacks or exacerbations of chronic pain), and preventive treatments (medication or other interventions designed to reduce the tendency to have attacks).
- Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment ...
The keys to caring for chronic migraine patients include:...
- Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment ...
10 Οκτ 2022 · It discusses the international guidelines on drug treatment for chronic migraine and evaluates non-drug treatments including behavioral and complementary therapies and lifestyle modifications.
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine – 2021 – link. Guidelines for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults – 2020 – link.
3 Ιουν 2024 · The International Headache Society Classification of Headache Disorders 3rd edition (ICHD-3) defines chronic migraine as a headache occurring on 15 or more days a month for more than three months, which on at least eight days a month has the features of a migraine headache. This seems simple enough.
30 Αυγ 2019 · Patients with chronic migraine require prophylactic therapy to reduce the frequency of migraine attacks, but the only currently available evidence-based prophylactic treatment options for chronic migraine are topiramate and onabotulinumtoxinA.
The keys to caring for chronic migraine patients include: (1) making a proper diagnosis; (2) identifying and eliminating exacerbating factors; (3) assessing for medication overuse (patients with chronic headache often overuse acute medications); and (4) continued management.
11 Σεπ 2024 · The IHS Guidelines for controlled trials of preventive treatment of chronic and episodic migraine suggest the use of a double-blind treatment phase lasting at least 12 weeks (62,63). These Guidelines suggest that trials of 24 weeks or longer may be useful in evaluating cumulative benefit, persistence of efficacy, adherence to treatment, safety ...
